Identification of a Novel Mutation (p.G328W) in the NR5A1 Gene in a Boy with 46, XY DSD: Case Report of Clinical, Endocrine and Genetic Features

Ortolano R1*, Baldazzi L1, Menabò S2, Balsamo A3, Cassio A2, Antona V4, Cimador M4, Corsello G4 and Giuffrè M4

1Department of Woman, Child Health and Urologic Diseases, Pediatric Unit, S.Orsola-Malpighi University Hospital, Italy
2Department of Medical and Surgical Sciences, Pediatric Unit, University of Bologna, Italy
3Center for Rare Endocrinologic Conditions (CARENDO BO; Endo-ERN), S.Orsola-Malpighi University Hospital, Bologna
4Department of Sciences for Health Promotion and Mother and Child Care G. D’Alessandro, Italy

*Corresponding author: Ortolano R, Department of Woman, Child Health and Urologic Diseases, Pediatric Unit, S.Orsola-Malpighi University Hospital, Via Masarénti 11, 40138 Bologna, Italy

Submission: September 15, 2017; Published: October 16, 2017

Abstract

**Introduction:** The gene NR5A1 (nuclear receptor subfamily 5 group A member 1, OMIM +184757) encodes for the Steroidogenic factor1 (SF1), a key regulator of the adrenal/gonadal development and function. Disorders/Differences of Sex Development (DSD) are defined as conditions where the chromosomal/anatomical, phenotypic sex is atypical. Heterozygous mutations of NR5A1 gene are associated, in 46, XY DSD patients, with a wide phenotypic spectrum of the external genitalia, with or without adrenal failure. Here we report a 46, XY newborn carrying a novel heterozygous NR5A1 mutation that presents with ambiguous genitalia without adrenal failure.

**Case Presentation:** newborn with ambiguous genitalia at birth (micropenis, hypospadias) with normal testosterone (T) response to hCG test, with a Müllerian remnant and bilateral inguinal immature gonads. Molecular analyses for AR, SRD5A2 genes did not reveal any mutation. NR5A1 sequence analysis identified a novel substitution c.982G>T (GGG>TGG) in exon 5, which results in the non-conservative p.G328W mutation, that arises de novo. Evaluation of the adrenal function was normal and no symptoms or signs of adrenal insufficiency have emerged during follow-up.

**Conclusion:** This is the first description of the p.G328W mutation (Sequence reference NC_000023.10) of the NR5A1 gene that causes the replacement of a highly conserved residue of the LBD (ligand binding domain) and very likely affects the SF1 action. This finding contributes to choose sex assignment and underlines the importance to perform the analysis of the NR5A1 gene also in 46, XY DSD patients with a PAIS-like phenotype.

**Keywords:** Disorders of sex development; Differences of sex development; DSD; NR5A1 gene; Steroidogenic factor-1; Ambiguous genitalia

**Abbreviations:** ACTH: adrenocorticotrophic hormone; Δ4A: Δ4Androstenedione; DHEAS: dehydroepiandrosterone sulphate; DHT: dihydrotestosterone; DSD: Disorders or Differences of Sex Development; HCG: Human Chorionic Gonadotropin; MRI: magnetic resonance imaging; PAIS: Partial Androgen Insensitivity Syndrome; SPL: Stretched Penile Length; T: Testosterone

**Introduction**

Disorders of Sex Development (DSD) comprise a variety of conditions where the chromosomal, gonadal or phenotypic sex are atypical [1]. Because of a diffused negative connotation of the term “disorders” perceived by some advocacy organizations, recently it has been proposed to prefer the word “differences” [2]. 46, XY DSD, in particular, consist of a wide range of phenotypes, from very low under virilization through various degrees of ambiguity, to complete female appearance. They are caused by partial or total gonadal dysgenesis, defects of androgen synthesis/action or other causes. To date, only the 50% of the cases receive a correct diagnosis, including the identification of the genetic/hormonal cause [3].

In the last 10 years, the importance of the Steroidogenic factor 1 (SF1) [4] as a crucial factor has increased and its implication in a wide spectrum of DSD phenotypes has emerged [5]. SF1 is one of the most precocious markers of the adrenal/gonadal development, initially identified as an orphan nuclear receptor. Key determinant of the tissue-specific expression of steroidogenic enzymes it binds a wide range of different phospholipid and sphingolipid ligands [6,7]. In mice and humans it is expressed very early in the urogenital ridge and continues to be highly expressed in the developing adrenal, gonad, ventromedial hypothalamus, and pituitary.

In male SF1 is necessary for testis determination and differentiation: for the formation of bi potential gonads, to activate the expression of anti-Müllerian hormone gene (AMH) in Sertoli cells [8] and to regulate the expression of steroid hormones in the Leydig cells. In female development, it is also actively present and participates in different steps of ovarian development and function: it is expressed in the granulosa and theca cells where it regulates...
genes required for ovarian steroidogenesis and follicle growth maturation [9]. SF1 has 461 amino acids and is encoded by the gene NR5A1 (nuclear receptor subfamily 5 group A member 1, OMIM + 184757) located at 9q33 and consisting of 7 exons.

The SF1 structure typically includes: a DNA binding domain (DBD) with two zinc fingers, a hinge region and a ligand-binding domain (LBD) [10]. NR5A1 mutations in 46,XY subjects may lead to various degree of undervirilization: first described in patients with Müllerian remnants and primary adrenal failure [11], subsequently over 50 mutations were reported mainly in 46,XY DSD individuals/infertile males, sometimes also resembling a PAIS/MAIS phenotype, with apparently normal adrenal function [12,13]. 46, XX females with NR5A1 mutations may present with or without primary adrenal and or ovarian insufficiency [14,15]. The NR5A1 mutations are usually present in heterozygous condition and very rarely in homozygosity, thus suggesting a potential dosage-dependent action of SF1 [16]. Different penetrance and variable inheritance pattern for NR5A1 mutations were also well documented among various families, thus indicating a complex phenotype expressivity [3]. This wide range of expressions enlarges the difficulties to establish a direct genotype-phenotype correlation [17] and hampers both the genetic counseling and the decisions making for management at the time of the diagnosis [2].

Any novel findings that enlarge the spectrum of cases is therefore helpful to improve the comprehension of the genotype-phenotype correlation. Here, we report a novel heterozygous substitution c.982G>T (GGG>TGG) in exon 5, which results in the p.G328W mutation, de novo, identified in a 46, XY DSD patient with severe undervirilization without adrenal insufficiency.

**Case Presentation**

The study was undertaken under an institutionally approved ethic protocol and informed consent was obtained from relatives. The patient was born at term by third pregnancy to healthy non-consanguineous parents. At birth the neonate presented with ambiguous genitalia: micropenis, single perineal urogenital opening representing a urogenital sinus [2], mild hyperpigmentation of labioscrotal folds without palpable gonads registered as female. Cytogenetic analysis revealed a 46, XY karyotype; therefore the infant was referred to our service at 20 days of life for 46, XY DSD. Physical examination revealed a stretched penile length (SPL) of 1.5cm, a single perineal urogenital opening, and palpable gonads in the labioscrotal folds (Figure 1 a-b). The external masculization score was 5.

Hormonal investigations showed a normal testosterone (T) response to hCG test (Table 1), a basal T/Δ4 Androstenedione (T/Δ4A) ratio of 7, 5, a basal T/dihydrotestosterone (T/DHT) ratio of 9, 5. Evaluation of the adrenal function indicated that basal cortisol (F) and dehydroepiandrosterone sulphate (DHEAS) were within normal ranges (Table 2) and no symptoms or signs of adrenal insufficiency have emerged during follow-up. Pelvic ultrasound showed testicular-like structures inside labioscrotal folds and a Müllerian remnant confirmed by pelvic magnetic resonance imaging (MRI) and by exploratory laparoscopy. Genitography disclosed a structure similar to a closed-end vagina.

**Table 1:** Laboratory response to hCG test at 3 months of life (1000 UI/day of hCG for 3 consecutive days).

<table>
<thead>
<tr>
<th></th>
<th>FSH (mUI/mL)</th>
<th>LH (mUI/mL)</th>
<th>E2 (pg/mL)</th>
<th>P (pg/mL)</th>
<th>T (ng/mL)</th>
<th>Δ4-A (ng/mL)</th>
<th>DHT (ng/mL)</th>
<th>DHEAS (μg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>5.6</td>
<td>3.69</td>
<td>&lt;5</td>
<td>0.167</td>
<td>1.5</td>
<td>0.2</td>
<td>0.158</td>
<td>6.81</td>
</tr>
<tr>
<td>T4</td>
<td>2.27</td>
<td>0.32</td>
<td>&lt;5</td>
<td>0.03</td>
<td>4.3</td>
<td>0.14</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

T0=basal value; T4= values at day 4 after hCG administration; E2= estradiol; P=progesterone. NA= not available

<table>
<thead>
<tr>
<th></th>
<th>FSH (mUI/mL)</th>
<th>LH (mUI/mL)</th>
<th>E2 (pg/mL)</th>
<th>T (ng/mL)</th>
<th>P (ng/mL)</th>
<th>DHEAS (μg/dL)</th>
<th>F at 8:00 AM (mg/dL)</th>
<th>F at 8:00 PM (mg/dL)</th>
<th>ACTH (pg/mL)</th>
<th>Renin (ng/mL/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>7.41</td>
<td>3.72</td>
<td>&lt;5</td>
<td>2.03</td>
<td>0.145</td>
<td>21.03</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>3</td>
<td>4.9</td>
<td>1.74</td>
<td>&lt;5</td>
<td>0.817</td>
<td>0.134</td>
<td>24.1</td>
<td>17.13</td>
<td>1.93</td>
<td>67.4</td>
<td>2.51</td>
</tr>
</tbody>
</table>

NA=not available; F= cortisol;

**Table 2:** Evaluation of gonadal and adrenal basal function.

Bilateral gonadal biopsy was performed at 4 months of age and the histological investigation showed: on the right gonad, immature testis with seminiferous tubules with Sertoli cells and only few germ cells; on the left gonad testicular parenchyma with seminiferous tubules containing few germ cells at the basal lamina. A partial gonadal dysgenesis, as suggested by the presence of a Müllerian remnant, cannot be excluded, probably more evident at the gonadal poles not included in the biopsy. No ovarian-like stroma was observed and OCT3/4 and CD117 immuno-histochemical markers were negative on both gonads.

Discussion

We present here an Italian case of 46, XY DSD with ambiguous genitalia at birth that harbors a novel NR5A1 mutation, without other mutations affecting AR & SRD5A2 genes. Patient phenotype was compatible with SF1 deficit Type II according Achermann’s classification [12]. He presents a normal male testosterone production after hCG test with a partial gonadal dysgenesis suggested by the presence of a Müllerian remnant. This mutation, p.G328W, originates de novo and affects a highly conserved and affects a highly conserved Gly328, located on one of the 2 beta sheets between the small Gly compared to the cumbersome Trp) and the de novo origin it is likely to speculate that this mutation is involved in the observed phenotype and functional studies of the mutant are in progress.

Surgery was programmed to descend testes and to correct urethral opening. There are reports of 46,XY DSD patients due to heterozygous mutations in the NR5A1 gene with male sex reassignment, orchiopexy and removal of Müllerian remnant [21]. Some studies [20,22] showed that patients with NR5A1 mutations could produce sufficient levels of testosterone to enter puberty spontaneously but with potential progressive gonadal dysgenesis resulting in oligo-azoospermia. Therefore it is recommended a regular monitoring of gonadal function in adolescence and adulthood, with eventual early cryopreservation of sperms. The risk for tumor development in patients with NR5A1 mutations is intrinsically increased due to testicular dysgenesis.

The risk is major on dysgenetic and undescended gonads [5] for the prolonged non-scrotal location of the gonads that has been recognized as an additional risk factor [23]. Our patient presents a gonadal histology characterized by some Sertoli cells and few spermatogonia and Leydig cells as described in other patients with SF1 deficit reported in literature [24,25] and with OCT3/4 negative that should indicate a lower tumor risk. In contrast to the relatively small number of NR5A1 changes reported in association with adrenal failure, heterozygous NR5A1 changes are emerging as a relatively frequent finding in patients with 46, XY DSD without adrenal insufficiency [26]. It has been proposed that genetic events...
leading to haploinsufficiency of NR5A1 could disrupt testicular development and function, whilst adrenal function remained intact [5].

Evaluation of the adrenal function in our patient showed normal basal cortisol, DHEAS and ACTH without any signs or symptoms of adren al insufficiency but he will have to perform an ACTH test and follow-up for adrenal function.

Conclusion

Heterozygous NR5A1 changes are emerging as a relatively frequent finding in patients with 46, XY DSD without adrenal failure [12], like our patient. In some individuals sex assignment is challenging and long-term studies of gender identity and psychosexual functioning are needed [27]. We report a novel mutation of NR5A1 involving a novel substitution c.982G>T (GGG>TGG) with glycine replacing tryptophan in exon 5 presenting with ambiguous genitalia without adrenal failure. It is the first description of the p.G328W mutation of the NR5A1 gene, which causes replacement of a highly conserved residue of the ligand binding domain and likely affects SF1 action. This finding helps in choosing sex assignment and underlines the importance of performing the analysis of NR5A1 gene also in 46, XY DSD patients with a PAIS-like orphan phenotype.

The long-term follow-up will supply useful information to understand if the choice of male sex of rearing has been appropriate. More studies are necessary to understand the phenotype/genotype correlation and to predict spontaneous pubertal development and potential future fertility.

Ethics Approval and Consent to Participate

The phenotypic data was collected from routine clinical examination and clinical records. Informed written consent for every genetical investigation performed to identify the underlying cause of DSD was obtained in accordance with protocols that comply with the Declaration of Helsinki. Therefore, no ethical approval was necessary.

Consent to Publish

Written informed consent for publication has been obtained by patient’s parents.

Availability of Data and Materials

DNA samples and biochemical results are stored in the Genetic Laboratory of Bologna and The official clinical chart of Palermo Hospital, respectively and will be available on specific request.

Authors’ Contributions

RO was responsible for the clinical and endocrine evaluation of the patient. BL performed genetic counselling and conducted diagnosis with RO. SM and LB performed the molecular genetics studies of the genes AR, SRD5A2 and NR5A1. RO, BL, AB, AC, MG, GC participated in the design of the study. MC was responsible for laparoscopic and biopsy investigations. RO, BL, MG conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgement

We wish to thank Prof Leendert H.J. Looijenga (JNI Afdeling Pathologie Erasmus MC University Medical Center Rotterdam) for his help in histological sample examination.

References
